The next generation of colloids: ready for "prime time"?
Nussmeier
Nancy A
NA
Searles
Bruce E
BE
D000418:Albumins / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000379:methods*; D003102:Colloids / Q000008:administration & dosage* / Q000009:adverse effects; D001026:Coronary Artery Bypass; D004730:Endothelium, Vascular / Q000187:drug effects / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage* / Q000009:adverse effects; D007249:Inflammation / Q000209:etiology / Q000276:immunology; D018836:Inflammation Mediators / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D010952:Plasma Substitutes / Q000008:administration & dosage* / Q000009:adverse effects; D010974:Platelet Aggregation / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D000418:Albumins; D015415:Biomarkers; D003102:Colloids; D006895:Hydroxyethyl Starch Derivatives; D018836:Inflammation Mediators; D010952:Plasma Substitutes